{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T13:27:10Z","timestamp":1794576430531,"version":"4.9.1"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005205","name":"Janssen Research &amp; Development LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.ahj.2024.08.011","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T23:05:12Z","timestamp":1724886312000},"page":"145-158","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"special_numbering":"C","title":["Milvexian vs apixaban for stroke prevention in atrial fibrillation: The LIBREXIA atrial fibrillation trial rationale and design"],"prefix":"10.1016","volume":"277","author":[{"given":"Sneha S.","family":"Jain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth W.","family":"Mahaffey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen S.","family":"Pieper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Potpara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian T.","family":"Ruff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hooman","family":"Kamel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basil S.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan H.","family":"Cornel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter R.","family":"Kowey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Horrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Strony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexei N.","family":"Plotnikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danshi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Donahue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Michael","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Gabriel","family":"Steg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Mehran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey I.","family":"Weitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Claiborne","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme J.","family":"Hankey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1903-0018","authenticated-orcid":false,"given":"Carolyn S.P.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2024.08.011_bib0001","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2024.08.011_bib0002","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1161\/CIR.0000000000001123","article-title":"Heart disease and stroke statistics-2023 update: a report from the American heart association","volume":"147","author":"Tsao","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2024.08.011_bib0003","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.113.005119","article-title":"Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010","volume":"129","author":"Chugh","year":"2014","journal-title":"Study. Circulation."},{"key":"10.1016\/j.ahj.2024.08.011_bib0004","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1093\/europace\/euac237","article-title":"Global burden of atrial fibrillation\/atrial flutter and its attributable risk factors from 1990 to 2019","volume":"25","author":"Dong","year":"2023","journal-title":"Europace"},{"key":"10.1016\/j.ahj.2024.08.011_bib0005","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: the Framingham study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke"},{"key":"10.1016\/j.ahj.2024.08.011_bib0006","doi-asserted-by":"crossref","first-page":"h7013","DOI":"10.1136\/bmj.h7013","article-title":"Atrial fibrillation as risk factor for cardiovascular disease and death in women compared with men: systematic review and meta-analysis of cohort studies","volume":"532","author":"Emdin","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.ahj.2024.08.011_bib0007","doi-asserted-by":"crossref","first-page":"i4482","DOI":"10.1136\/bmj.i4482","article-title":"Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis","volume":"354","author":"Odutayo","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.ahj.2024.08.011_bib0008","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1016\/j.jacc.2018.04.013","article-title":"Stroke prevention in nonvalvular atrial fibrillation: a stakeholder perspective","volume":"71","author":"Alkhouli","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2024.08.011_bib0009","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2147\/CLEP.S4794","article-title":"Atrial fibrillation in patients with ischemic stroke: a population-based study","volume":"1","author":"Thygesen","year":"2009","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.ahj.2024.08.011_bib0010","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2024.08.011_bib0011","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2024.08.011_bib0012","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2024.08.011_bib0013","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2024.08.011_bib0014","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.026723","article-title":"Trends in oral anticoagulant use among 436 864 patients with atrial fibrillation in community practice, 2011 to 2020","volume":"11","author":"Navar","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ahj.2024.08.011_bib0015","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1016\/j.jacc.2017.03.540","article-title":"Influence of direct oral anticoagulants on rates of oral anticoagulation for atrial fibrillation","volume":"69","author":"Marzec","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2024.08.011_bib0016","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.17156","article-title":"Analysis of oral anticoagulant dosing and adherence to therapy among patients with nonvalvular atrial fibrillation","volume":"6","author":"Rymer","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ahj.2024.08.011_bib0017","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s12325-022-02333-9","article-title":"Risk and management of bleeding complications with direct oral anticoagulants in patients with atrial fibrillation and venous thromboembolism: a narrative review","volume":"40","author":"Ballestri","year":"2023","journal-title":"Adv Ther"},{"key":"10.1016\/j.ahj.2024.08.011_bib0018","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.120.007230","article-title":"Bleeding risk of direct oral anticoagulants in patients with heart failure and atrial fibrillation","volume":"14","author":"Jackevicius","year":"2021","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.ahj.2024.08.011_bib0019","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1160\/TH10-05-0307","article-title":"Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis","volume":"105","author":"Salomon","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ahj.2024.08.011_bib0020","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1182\/blood-2007-10-120139","article-title":"Reduced incidence of ischemic stroke in patients with severe Factor XI deficiency","volume":"111","author":"Salomon","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ahj.2024.08.011_bib0021","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1182\/blood-2016-09-742262","article-title":"Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events","volume":"129","author":"Preis","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ahj.2024.08.011_bib0022","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1056\/NEJM200003093421004","article-title":"High levels of coagulation Factor XI as a risk factor for venous thrombosis","volume":"342","author":"Meijers","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2024.08.011_bib0023","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","article-title":"Milvexian for the prevention of venous thromboembolism","volume":"385","author":"Weitz","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2024.08.011_bib0024","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1474-4422(23)00403-9","article-title":"Safety and efficacy of Factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial","volume":"23","author":"Sharma","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ahj.2024.08.011_bib0025","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","article-title":"Safety of the oral Factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study","volume":"399","author":"Piccini","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2024.08.011_bib0026","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0140-6736(22)01588-4","article-title":"Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"400","author":"Shoamanesh","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2024.08.011_bib0027","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1161\/CIRCULATIONAHA.122.061612","article-title":"A multicenter, phase 2, randomized, placebo-controlled, double-blind, parallel-group, dose-finding trial of the oral Factor XIa inhibitor asundexian to prevent adverse cardiovascular outcomes following acute myocardial infarction","volume":"16","author":"Rao","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2024.08.011_bib0028","series-title":"Presented at: AHA","article-title":"AZALEA-TIMI 71-a multicenter, randomized, active-controlled study to evaluate the safety and tolerability of two blinded doses of abelacimab compared with open-label rivaroxaban in patients with atrial fibrillation","author":"Ruff","year":"2023"},{"key":"10.1016\/j.ahj.2024.08.011_bib0029","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jama.2019.20687","article-title":"Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial","volume":"323","author":"Weitz","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2024.08.011_bib0030","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Factor XI antisense oligonucleotide for prevention of venous thrombosis","volume":"372","author":"Buller","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2024.08.011_bib0031","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2105872","article-title":"Abelacimab for prevention of venous thromboembolism","volume":"385","author":"Verhamme","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2024.08.011_bib0032","unstructured":"European Clinical Trials Information Network. Examining new drug efficiency in avoiding blood clots post knee surgery. https:\/\/clinicaltrials.eu\/trial\/ct-eu-00057615\/. Accessed 30 June 2024."},{"key":"10.1016\/j.ahj.2024.08.011_bib0033","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1021\/acs.jmedchem.1c00613","article-title":"Discovery of milvexian, a high-affinity, orally bioavailable inhibitor of factor XIa in clinical studies for antithrombotic therapy","volume":"65","author":"Dilger","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.ahj.2024.08.011_bib0034","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/cts.13148","article-title":"First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor","volume":"15","author":"Perera","year":"2022","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.ahj.2024.08.011_bib0035","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3390\/hematolrep16010016","article-title":"Drug\u2013drug interactions of FXI inhibitors: clinical relevance","volume":"16","author":"Ferri","year":"2024","journal-title":"Hematol Rep"},{"key":"10.1016\/j.ahj.2024.08.011_bib0036","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1038\/s41598-022-08768-y","article-title":"Safety, pharmacokinetics, and pharmacodynamics of milvexian in healthy Japanese participants","volume":"12","author":"Perera","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.ahj.2024.08.011_bib0037","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1161\/CIRCULATIONAHA.117.029081","article-title":"Female sex is a risk modifier rather than a risk factor for stroke in atrial fibrillation: should we use a CHA(2)DS(2)-VA score rather than CHA(2)DS(2)-VASc?","volume":"137","author":"Nielsen","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2024.08.011_bib0038","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2024.08.011_bib0039","series-title":"Presented at: ISTH","article-title":"Characterizing the relationship between milvexian exposure, efficacy, and safety in total knee replacement patients to support milvexian phase 3 dose selection","author":"Zhou","year":"2024"},{"key":"10.1016\/j.ahj.2024.08.011_bib0040","series-title":"Presented at: ISTH","article-title":"A model-based meta-analysis leveraging total knee replacement (TKR) data for selection of the milvexian dose for a phase 3 study in participants with atrial fibrillation","author":"Alexander","year":"2024"},{"key":"10.1016\/j.ahj.2024.08.011_bib0041","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ahj.2009.07.035","article-title":"Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale","volume":"159","author":"Lopes","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2024.08.011_bib0042","unstructured":"Bayer. OCEANIC-AF study stopped early due to lack of efficacy. 2023. https:\/\/www.bayer.com\/media\/en-us\/oceanic-af-study-stopped-early-due-to-lack-of-efficacy\/. Accessed 7 June 2024."},{"key":"10.1016\/j.ahj.2024.08.011_bib0043","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/jth.15588","article-title":"Milvexian, an orally bioavailable, small-molecule, reversible, direct inhibitor of factor XIa: in vitro studies and in vivo evaluation in experimental thrombosis in rabbits","volume":"20","author":"Wong","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ahj.2024.08.011_bib0044","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1111\/jth.15700","article-title":"Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa","volume":"20","author":"Heitmeier","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ahj.2024.08.011_bib0045","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1111\/bcp.15230","article-title":"Pharmacokinetics, pharmacodynamics and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: a randomized phase 1 multiple-dose study","volume":"88","author":"Kubitza","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ahj.2024.08.011_bib0046","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ahj.2024.08.011_bib0047","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1538-7836.2009.03678.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients","volume":"8","author":"Schulman","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ahj.2024.08.011_bib0048","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1161\/01.CIR.84.2.527","article-title":"Stroke prevention in atrial fibrillation study. Final results","volume":"84","year":"1991","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2024.08.011_bib0049","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/0735-1097(91)90585-W","article-title":"Canadian atrial fibrillation anticoagulation (CAFA) study","volume":"18","author":"Connolly","year":"1991","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2024.08.011_bib0050","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1056\/NEJM199011293232201","article-title":"The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation","volume":"323","author":"Singer","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2024.08.011_bib0051","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJM199211123272002","article-title":"Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans affairs stroke prevention in nonrheumatic atrial fibrillation investigators","volume":"327","author":"Ezekowitz","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2024.08.011_bib0052","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/0140-6736(93)92358-Z","article-title":"Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke","volume":"342","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2024.08.011_bib0053","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0140-6736(89)91200-2","article-title":"Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study","volume":"1","author":"Petersen","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2024.08.011_bib0054","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1111\/bcp.13280","article-title":"Defining the noninferiority margin and analysing noninferiority: an overview","volume":"83","author":"Althunian","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ahj.2024.08.011_bib0055","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1056\/NEJMc2208614","article-title":"Tranexamic acid in patients undergoing noncardiac surgery","volume":"387","author":"Baker","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2024.08.011_bib0056","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1056\/NEJMoa1606424","article-title":"Tranexamic acid in patients undergoing coronary-artery surgery","volume":"376","author":"Myles","year":"2017","journal-title":"N Engl J Med"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870324002060?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870324002060?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T23:56:15Z","timestamp":1726185375000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870324002060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":56,"alternative-id":["S0002870324002060"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2024.08.011","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Milvexian vs apixaban for stroke prevention in atrial fibrillation: The LIBREXIA atrial fibrillation trial rationale and design","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2024.08.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}